Back to Search
Start Over
The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
- Source :
-
Pharmacology & therapeutics [Pharmacol Ther] 2014 Mar; Vol. 141 (3), pp. 283-99. Date of Electronic Publication: 2013 Nov 01. - Publication Year :
- 2014
-
Abstract
- Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that was deorphanized in 1995. The generation of specific agonists, antagonists and receptor deficient mice and rats has enabled progress in elucidating the biological functions of N/OFQ. Additionally, radio-imaging technologies have been advanced for investigation of this system in animals and humans. Together with traditional neurobehavioral techniques, these tools have been utilized to identify the biological significance of the N/OFQ system and its interacting partners. The present review focuses on the role of N/OFQ in the regulation of feeding, body weight homeostasis, stress, the stress-related psychiatric disorders of depression and anxiety, and in drug and alcohol dependence. Critical evaluation of the current scientific preclinical literature suggests that small molecule modulators of nociceptin opioid peptide receptors (NOP) might be useful in the treatment of diseases related to these biological functions. In particular, the literature data suggest that antagonism of NOP receptors will produce anti-obesity and antidepressant activities in humans. However, there are also contradictory data discussed. The current literature on the role of N/OFQ in anxiety and addiction, on the other hand points primarily to a role of agonist modulation being potentially therapeutic. Some drug-like molecules that function either as agonists or antagonists of NOP receptors have been optimized for human clinical study to test some of these hypotheses. The discovery of PET ligands for NOP receptors, combined with the pharmacological tools and burgeoning preclinical data set discussed here bodes well for a rapid advancement of clinical understanding and potential therapeutic benefit.<br /> (© 2013.)
- Subjects :
- Animals
Anxiety drug therapy
Anxiety physiopathology
Humans
Mice
Mood Disorders drug therapy
Mood Disorders physiopathology
Narcotic Antagonists
Obesity drug therapy
Obesity physiopathology
Rats
Receptors, Opioid agonists
Stress, Psychological drug therapy
Stress, Psychological physiopathology
Substance-Related Disorders drug therapy
Substance-Related Disorders physiopathology
Nociceptin Receptor
Nociceptin
Drug Design
Opioid Peptides metabolism
Receptors, Opioid metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-016X
- Volume :
- 141
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Pharmacology & therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 24189487
- Full Text :
- https://doi.org/10.1016/j.pharmthera.2013.10.011